-
PurposeLentiviral CRISPR-Cas9 delivery for SpCas9 and sgRNA, Puromycin resistance, SFFV Promoter driven
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 57829 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepLKO.005
- Total vector size (bp) 13615
-
Vector typeLentiviral, CRISPR
-
Selectable markersPuromycin
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)Stbl3
-
Copy numberHigh Copy
Gene/Insert 1
-
Gene/Insert nameSpCas9
-
SpeciesS. pyogenes
-
Insert Size (bp)4300
-
Tag
/ Fusion Protein
- FLAG (N terminal on insert)
Gene/Insert 2
-
Gene/Insert nameSp sgRNA scaffold
-
Insert Size (bp)75
Gene/Insert 3
-
Gene/Insert nameSFFV
-
Alt nameSpleen Focus Forming Virus promoter
-
SpeciesSynthetic
-
Insert Size (bp)415
Gene/Insert 4
-
Gene/Insert nameP2A-PAC
-
Alt namePuromycine resistance gene
-
SpeciesSynthetic
-
Insert Size (bp)750
Resource Information
-
Supplemental Documents
-
Article Citing this Plasmid
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
Please note that this plasmid contains the 1.9kb stuffer from the pLKO.005 vector backbone between the BsmBI sites used for sgRNA cloning.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pL-CRISPR.SFFV.PAC was a gift from Benjamin Ebert (Addgene plasmid # 57829 ; http://n2t.net/addgene:57829 ; RRID:Addgene_57829) -
For your References section:
Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Heckl D, Kowalczyk MS, Yudovich D, Belizaire R, Puram RV, McConkey ME, Thielke A, Aster JC, Regev A, Ebert BL. Nat Biotechnol. 2014 Jun 22. doi: 10.1038/nbt.2951. 10.1038/nbt.2951 PubMed 24952903